1 BTC
=
- USD
Sonnet BioTherapeutics Holdings, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Sonnet BioTherapeutics Holdings, Inc. Common Stock
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Market Statistics
Trading Metrics
How to Buy SONN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SONN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesHyperliquid Strategies Inc completed a business combination with Sonnet BioTherapeutics, creating a digital asset treasury reserve company. The merged entity will trade under the ticker 'PURR' on Nasdaq and aims to provide investors exposure to the HYPE token ecosystem.
Sonnet BioTherapeutics Holdings has received stockholder approval for its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, marking a significant corporate development for the oncology-focused biotechnology company.
Heights Capital Management established a new $16.15 million position in ImmunityBio, buying 6,565,709 shares, representing 4.4% of its assets under management. The investment suggests potential confidence in the company's clinical-stage immunotherapy pipeline.
Sonnet BioTherapeutics, a clinical-stage oncology company, will present at the MedInvest Biotech & Pharma Conference. The company is developing immunotherapeutic drugs using its FHAB platform, with lead program SON-1010 being studied for ovarian cancer treatment in collaboration with Roche.
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for three companies: Sonnet BioTherapeutics, First Community Corporation, and Monogram Technologies, related to their recent merger or sale transactions.
